The effects of phytosomal curcumin supplementation on clinical symptoms, and inflammatory and oxidative stress biomarkers in patients with migraine: A protocol for a randomized double-blind placebo-controlled trial | ||
| Avicenna Journal of Phytomedicine | ||
| دوره 13، شماره 1، فروردین و اردیبهشت 2023، صفحه 45-57 اصل مقاله (595.99 K) | ||
| نوع مقاله: Original Research Article | ||
| شناسه دیجیتال (DOI): 10.22038/ajp.2022.21242 | ||
| نویسندگان | ||
| Mehrnaz Shojaei1؛ Amirhossein Sahebkar2؛ Fariborz Khorvash3؛ Soheil Fallahpour4؛ Gholamreza Askari5؛ Mohammad Bagherniya* 5 | ||
| 1Student Research Committee, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran | ||
| 2Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 3Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran | ||
| 4Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran | ||
| 5Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. Anesthesia and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran | ||
| چکیده | ||
| Objective: Migraine is one of the most common diseases. Curcumin with anti-oxidative and anti-neuroinflammatory properties might have beneficial effects in migraine patients. This study will be conducted to evaluate the effects of a phytosomal preparation of curcumin on clinical signs, oxidative stress, and inflammatory parameters in patients with migraine. Materials and Methods: This is a randomized, double-blind, placebo-controlled, clinical trial in which, 60 patients with migraine will be assigned to receive a daily dose of 250 mg of phytosomal curcumin for 8 weeks (intervention group) or 250 mg maltodextrin as a placebo for the same duration (control group). Before and after the study, frequency, duration, and severity of the attacks, quality of life and sleep, mood status, high-sensitivity C-reactive protein (hs-CRP), Nitric Oxide (NO), and oxidative stress factors will be measured. Conclusion: It seems that phytosomal formulation of curcumin (a solid dispersion preparation of curcumin with phosphatidylserine) with high bioavailability, can cross the blood-brain barrier (BBB) and result in decreased neuroinflammation, oxidative stress, and neurotoxicity. This way, phytosomal curcumin might lead to reduction of headaches and other complications of migraine and increase the quality of life of patients with migraine. | ||
| کلیدواژهها | ||
| Curcumin؛ Phytosomal curcumin؛ Migraine؛ Inflammation؛ Headache | ||
| مراجع | ||
|
Abdolahi M, Karimi E, Sarraf P, Tafakhori A, Siri G, Salehinia F, Sedighiyan M, Asanjarani B, Badeli M, Abdollahi H, Yoosefi N, Yousefi A, Rad S, Djalali M. 2021. The omega-3 and Nano-curcumin effects on vascular cell adhesion molecule (VCAM) in episodic migraine patients: a randomized clinical trial. BMC Res Notes, 14: 283. Agosti R. 2018. Migraine burden of disease: from the patient's experience to a socioeconomic View. Headache, 58 Suppl 1: 17- 32. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. 2013. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther, 138: 155-175. Alstadhaug K, Salvesen R, Bekkelund S. 2007. Insomnia and circadian variation of attacks in episodic migraine. Headache, 47: 1184- 1188. Atabaki M, Shariati-Sarabi Z, TavakkolAfshari J, Taghipour A, Jafari MR, Nikpoor AR, Mohammadi M. 2022. Curcumin as an effective suppressor of miRNA expression in patients with knee osteoarthritis. Avicenna J Phytomed, 12: 346-356. Mythri RB, Srinivas Bharath MM. 2012. Curcumin: a potential neuroprotective agent in Parkinson's disease. Curr Pharm Des, 18: 91-99. Bagherniya M, Nobili V, Blesso CN, Sahebkar A. 2018. Medicinal plants and bioactive natural compounds in the treatment of nonalcoholic fatty liver disease: A clinical review. Pharmacol Res, 130: 213-240. Borkum JM. 2016. Migraine triggers and oxidative stress: A narrative review and synthesis. Headache, 56: 12-35. Borkum JM. 2018. Harnessing migraines for neural regeneration. Neural Regen Res, 13: 609-615. Bruno PP, Carpino F, Carpino G, Zicari A. 2007. An overview on immune system and migraine. Eur Rev Med Pharmacol Sci, 11: 245-248. Bulboacă AE, Bolboacă SD, Bulboacă AC, Porfire AS, Tefas LR, Suciu SM, Dogaru G, Stănescu IC. 2019. Liposomal curcumin enhances the effect of naproxen in a rat model of migraine. Med Sci Monit, 25: 5087-5097. Bulboacă AE, Bolboacă SD, Stănescu LC, Sfrângeu CA, Bulboacă AC. 2017. Preemptive analgesic and antioxidative effect of curcumin for experimental migraine. Biomed Res Int, 2017: 4754701. Chainani-Wu N. 2003. Safety and antiinflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med, 9: 161-168. Phytosomal curcumin and Migraine AJP, Vol. 13, No. 1, Jan-Feb 2023 55 Chan A, Tetzlaff WJM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar W, Summerskill WS, Groves KF, Schulz HC, Sox FW, Rennie RD, Moher D. 2013. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med, 158: 200-207. Cole GM, Yang F, Lim GP, Cummings JL, Masterman DL, Frautschy SA. 2003. A rationale for curcuminoids for the prevention or treatment of Alzheimer's disease. Curr Med Chem Immunol Endocr Metab Agents, 3: 15-25. D'Amico D, Tepper SJ. 2008. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat, 4: 1155-1167. Economics, Deloitte Access. 2018. Migraine in Australia whitepaper. Canberra: Deloitte Access Economics Report. Available in: https://www2.deloitte.com/au/en/pages/eco nomics/articles/migraine-australiawhitepaper.html. Edvinsson L, Haanes KA, Warfvinge K. 2019. Does inflammation have a role in migraine? Nat Rev Neurol, 15: 483-490. Farhadi ZS, Alidoost M, Behzadifar R, Mohammadibakhsh N, Khodadadi R, Sepehrian R, Sohrabi M, Taheri Mirghaed M, Salemi M, Ravaghi H, Behzadifar M. 2016. The prevalence of migraine in Iran: A systematic review and meta-analysis. Iran Red Crescent Med J, 18: e40061. Farhood B, Mortezaee K, Goradel H, Khanlarkhani N, Salehi E, Nashtaei MS, Najafi M, Sahebkar A. 2019. Curcumin as an anti-inflammatory agent: Implications to radiotherapy and chemotherapy. J Cell Physiol, 234: 5728-5740. Farrahi Moghaddam J, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. 2012. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath, 16: 79-82. Finocchi C, Sivori G. 2012. Food as trigger and aggravating factor of migraine. Neurol Sci, 33: 77-80. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM. 2001. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol aging, 22: 993-1005. Gerring ZF, Powell JE, Montgomery GW, Nyholt DR. 2018. Genome-wide analysis of blood gene expression in migraine implicates immune-inflammatory pathways. Cephalalgia, 38: 292-303. Ghasemi SZ, Memarzia A, Behrouz S, Gholamnezhad Z, Boskabady MH. 2022. Comparative effects of Curcuma longa and curcumin on paraquat-induced systemic and lung oxidative stress and inflammation in rats. Avicenna J Phytomed, 12: 414-424. Ghorbani A, Chitsaz A. 2011. Comparison of validity and reliability of the Migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population. Iran J Neurol, 10: 39-42. Glade M, Smith K. 2015. Phosphatidylserine and the human brain. Nutrition, 31: 781- 786. Hauge AW, Kirchmann M, Olesen J. 2010. Trigger factors in migraine with aura. Cephalalgia, 30: 346-353. Hewlings SJ, Kalman DS. 2017. Curcumin: A review of its effects on human health. Foods, 6: 92. Hsu CH, Cheng AL. 2007. Clinical studies with curcumin. Adv Exp Med Biol, 595: 471-480. Asha J, Rongqian Wu, Zhou M, Wang P. 2008. Mechanism of the anti-inflammatory effect of curcumin: PPAR-γ activation. PPAR Res, 2007: 89369. Javandoost A, Afshari A, Saberi-Karimian M, Sahebkar A, Safarian H, Moammeri M, Fathi Dizaji B, Tavalaei SH, Ferns GA, Pasdar A. 2018. The effects of curcumin and a modified curcumin formulation on serum cholesteryl ester transfer protein concentrations in patients with metabolic syndrome: A randomized, placebocontrolled clinical trial. Avicenna J Phytomed, 8: 330-337. Jette N, Patten S, Williams J, Becker W, Wiebe S. 2008. Comorbidity of migraine and psychiatric disorders--a national population-based study. Headache, 48: 501-516. Karimi L, Crewther SG, Wijeratne T, Evans AE, Afshari L, Khalil H. 2020. The prevalence of migraine with anxiety among genders. Front Neurol, 11: 569405. Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. 2018. Poor medical care for people with migraine in Europe - evidence Shojaei et al. AJP, Vol. 13, No. 1, Jan-Feb 2023 56 from the Eurolight study. J Headache Pain, 19: 10. Kheiripour N, Khodamoradi Z, Ranjbar A, Borzouei SH. 2021. The positive effect of short-term nano-curcumin therapy on insulin resistance and serum levels of afamin in patients with metabolic syndrome. Avicenna J Phytomed, 11: 146- 153. Kumar Vikas. 2006. Potential medicinal plants for CNS disorders: an overview. Phytother Res, 20: 1023-1035. Kursun O, Yemisci M, Maagdenberg AA, Karatas H. 2021. Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain, 22: 55. Lantéri-Minet M, Mudge DMG, Cottrell S. 2011. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia, 31: 837-850. Linde M A, Gustavsson LJ, Stovner TJ, Steiner J, Katsarava BZ, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Torre ER, Tassorelli C, Andrée C. 2012. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol, 19: 703- 711. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. 2007. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68: 343- 349. Lovibond PF, Lovibond SH. 1995. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther, 33: 335-343. Mayans L, Walling A. 2018. Acute migraine headache: Treatment strategies. Am Fam Physician, 97: 243-251. Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. 2017. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother, 85: 102- 112. Mohseni M, Sahebkar A, Askari G, Johnston TP, Alikiaii B, Bagherniya M. 2021. The clinical use of curcumin on neurological disorders: An updated systematic review of clinical trials. Phytother Res, 35: 6862- 6882. Mortezaee K, Salehi E, Mirtavoos-mahyari H, E. Motevaseli M, Najafi B, Farhood R, Rosengren J, Sahebkar A. 2019. Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. J Cell Physiol, 234: 12537-12550. Munoz-Ceron J, Marin-Careaga V, Peña L, Mutis J, Ortiz G. 2019. Headache at the emergency room: Etiologies, diagnostic usefulness of the ICHD 3 criteria, red and green flags. PLoS One, 14: e0208728. Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A. 2014. Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: Positive results of a randomized double-blind placebocontrolled trial. Drug Res (Stuttg), 65: 567- 573. Park SY, Darrick SHL. 2002. Discovery of natural products from Curcuma l onga that protect cells from beta-amyloid insult: A drug discovery effort against Alzheimer's disease. J Nat Prod, 65: 1227-1231. Parohan M, Sarraf P, Javanbakht MH, Foroushani AR, Ranji-Burachaloo S, Djalali M. 2019. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, doubleblind trial. Nutr Neurosci, 24: 317-326. Parsamanesh N, Moossavi M, Bahrami A, Butler AE, Sahebkar A. 2018. Therapeutic potential of curcumin in diabetic complications. Pharmacol Res, 136: 181- 193. Puledda F, Shields K. 2018. Nonpharmacological approaches for migraine. Neurotherapeutics, 15: 336-345. Rezaie S, Askari G, Khorvash F, Tarrahi M, Amani R. 2021. Effects of curcumin supplementation on clinical features and inflammation, in migraine patients: A double-blind controlled, placebo randomized clinical trial. Int J Prev Med, 12: 161. Samani S, Joukar B. 2007. A study on the reliability and validity of the short form of the depression anxiety stress scale (DASS21). Shiraz Journal of Social and Human Sciences, 26: 65-77. Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB. 2006. Disability and poor quality Phytosomal curcumin and Migraine AJP, Vol. 13, No. 1, Jan-Feb 2023 57 of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med, 166: 2109-2116. Sedighiyan M, Abdolahi M, Jafari E, Vahabi Z, Sohrabi Athar S, Hadavi S, Narimani Zamanabadi M, Yekaninejad MS, Djalali M. 2022. The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study. BMC Res Notes, 15: 189. Shakeri A, Cicero AFG, Panahi Y, Mohajeri M, Sahebkar A. 2019. Curcumin: A naturally occurring autophagy modulator. J Cell Physiol, 234: 5643-5654. Sommer C, Kress M. 2004. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett, 361: 184-187. Sparreboom A, Cox M, Acharya M, Figg W. 2004. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol, 22: 2489- 2503. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, Ansha MG, Barac A, Bensenor IM, Doan LP. 2018. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 17: 954-976. Tajti J, Párdutz A, Vámos E, Tuka B, Kuris A, Bohár Z, Fejes A, Toldi J, Vécsei L. 2011. Migraine is a neuronal disease. J Neural Transm (Vienna), 118: 511-524. Edilia T, Soto V, Ortiz-Vega KM, ZarcoMárquez G, Molina-Jijón E, CristóbalGarcía M, Santamaría J, García-Niño WR, Correa F, Zazueta C. 2012. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid Med Cell Longev, 2012: 269039. Theeler B, Kenney JK, Prokhorenko OA, Fideli US, Campbell W, Erickson JC. 2010. Headache triggers in the US military. Headache, 50: 790-794. Thiyagarajan M, Sharma SS. 2004. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci, 74: 969-985. Angeliki V, Pavlović JM. 2018. Sleep disorders and migraine: review of literature and potential pathophysiology mechanisms. Headache, 58: 1030-1039. Yilmaz IA, Ozge A, Erdal ME, Edgünlü TG, Cakmak SE, Yalin OO. 2010. Cytokine polymorphism in patients with migraine: some suggestive clues of migraine and inflammation. Pain Med, 11: 492-497. Zandifar A, Masjedi SS, Haghdoost F, Asgari F, Manouchehri N, Banihashemi M, Najafi MR, Ghorbani A, Zolfaghari B, Gholamrezaei A, Shaygannejad V, Saadatnia M. 2013. The psychometric properties of the persian migraine-specific quality of life questionnaire version 2.1 in episodic and chronic migraines. Sci World J, 2013: 950245. Zareie A, Sahebkar A, Khorvash F, Bagherniya M, Hasanzadeh A, Askari G. 2020. Effect of cinnamon on migraine attacks and inflammatory markers: A randomized double-blind placebocontrolled trial. Phytother Res, 34: 2945- 2952. Zhang X , Zhang H, Si L, Li Y. 2011. Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer’s disease. Pharmacol Rep, 63: 1101-1108 | ||
|
آمار تعداد مشاهده مقاله: 14,036 تعداد دریافت فایل اصل مقاله: 10,182 |
||
